-
a complex disorder with no single factor as the cause
metabolic syndrome
-
2 main characteristics of metabolic syndrome
- abdominal obesity
- insulin resistance
-
4 metabolic risk factors for metabolic syndrome
- atherogenic dyslipidemia
- hypertension
- high plasma glucose
- a prothrombic and pro-inflammatory state
-
major cause of death in the western world
vascular disease dominated by artherosclerotic heart disease
-
the obvious indicator for susceptibility to plaque buildup
hyperlipidemia
-
5 causes of hyperlipidemia
- diet
- liver disease
- kidney disease
- pancreas disease
- thyroid disease
-
degenerative changes in the intima of medium and large vessels
artherosclerosis
-
2 characteristics of artherosclerosis
- plaque
- decrease lumen diameter
-
what leads to the lipid rich core of plaque
- inflammation
- macrophage activation
-
intraplaque thrombus
stable angina
-
mural thrombus
unstable angina
-
occlusive thrombus
acute myocardial infarction
-
macromolecules that consist of triglycerides and cholesterol non-covalently associated with protein and carbohydrates
lipoproteins
-
natural molecule of lipid
cis fatty acids
-
produced by partial hydrogenation of unsaturated oils, margarines, vegetable shortening, frying oils
trans fatty acids
-
what is the implication of trans fat
elevated LDL
-
their source is exogenous fat in the diet
90% triglycerides by weight
chylomicrons
-
their source is the liver
60% triglycerides
VLDL
-
rapidly produced from chylomicrons and VLDL
IDL
-
major cholesterol carrying protein
50% cholesterol and 10% triglycerides
major concern in hyperlipidemic states and diseases
LDL
-
25% cholesterol and 50% protein and accounts for 17% of serum cholesterol
HDL
-
type of hyperlipoproteinemia with abnormal amounts of chylomicrons resulting in plasma with a creamy top
massive elevated triglycerides
I
-
no drugs to treat this type of hyperlipoprotein, treat by decreasing dietary fat
I
-
cause of this type of hyperlipoproteinemias is decrease in lipoprotein lipase that clears plasma of chylomicrons
I
-
type of hyperlipoprotein with elevated beta-lipoproteins and LDL
normal triglycerides
heavily elevated total cholesterol
clear plasma
IIa
-
type of hyperlipoproteinemia with elevated pre-beta-lipoproteins and LDL+VLDL
triglycerides slightly elevated
heavily elevated total cholesterol
slightly turbid plasma
IIb
-
type of hyperlipoproteinemia that is very common
familial autosomal dominant abnormality often expressed at infanct
II
-
type of hyperlipoproteinemias that cause appears to be disturbed catabolism of LDL
II
-
type of hyperlipoproteinemia with heavily elevated beta-lipoproteins
abnormal VLDL/LDL compostion
elevated trilycerides and total cholesterol
III
-
type of hyperlipoproteinemia that is rare
familial inheritance
III
-
type of hyperlipoproteinemia that is treated with dietary restrictions and drugs
all but type I
-
type of hyperlipoproteinemia with elevated pre-beta-lipoproteins and VLDL
moderate to heavy elevated triglycerides
normal to elevated total cholesterol
turbid plasma
IV
-
type of hyperlipoproteinemia that has an unknown metabolic defect
IV
-
type of hyperlipoproteinemia with elevated pre-beta lipoproteins with chylomicrons present
VLDL elevated
massively elevated TG
slightly elevated total cholesterol
turbid plasma with floating layer of chylomicrons
V
-
type of hyperlipoproteinemia with a metabolic defect unknow however clearance of dietary fat is impaired
V
-
3 general considerations when considering how to approach antihyperlipidemic agents
- identify the type of hyperlipidemia
- estabish baseline cholesterol
- institute revised diet, weight loss, and increased physical activity
-
5 drug therapy approaches for hyperlipidemia
- first choice drugs (statins or HMG-CoA reductase inhibitors
- consider ERT
- combination drug therapy
- fibric acid type of drugs
- thyroid hormone - drugs of last resort
-
why are fibric acids and HMG-CoA reductase inhibitors not recommended
- myopathy
- rhabdomyolysis
- renal failure
-
rate limiting step in the synthesis of cholesterol
HMG-CoA reductase
-
generally accepted that lowering of cholesterol levels is best accomplished by
reducing LDL levels
-
what 2 means do HMG-CoA reductase inhibitors contribute to lowering of LDL
- decreased cholesterol synthesis by blocking the HMG-CoA reductase active site
- leads to an increase hepatic LDL receptros causing increase processing of plasma LDL
-
why are statins contraindicated in pregnancy
you need cholesterol to build little johnny's cells
-
side effect of statins
photosensitivity
-
can you drink alcohol when on statins
no
-
lipophilic statins
- atorvastatin
- lovastatin
- simvastatin
-
which statins are more hydorphilic
- pravastatin
- rosuvastatin
- fluvastatin
-
what happens when cholesterol levels drop below 100mg/dl
anxiety and clinical depression
-
this is used as a starting material for statin class synthesis and is isolated from penicillium citrinum
compactin
-
a naturally occuring lipid-soluble, vitamin like substance found in the inner mitochondrial anc cellular membranes and in blood
CoEnzyme Q10
-
in what sense can fibrates be used cardiovascularly
reduce the occurence of nonfatal MI but have no significant effects on other adverse CV outcomes
-
new mechanism by which fibrates may act
T1Rs inhibition
-
gene mutation that can have an affect on statin induced myopathy
SLCO1B1 - a gene that encodes for the protein involved in the transport of statins from the blood into the liver
|
|
